Cost effectiveness of urea-based DCB treatment for CLTI patients “extremely important”


A range of experts, including Koen Deloose (Dendermonde, Belgium), Thomas Zeller (Bad Krozingen, Germany), Marianne Brodmann (Graz, Austria) and Antonio Micari (Messina, Italy), talk to Vascular News about how the latest data supporting the cost-effectiveness of the IN.PACT Admiral drug-coated balloon (DCB; Medtronic) is helping to drive the adoption of this treatment strategy in chronic limb threatening ischaemia (CLTI) patients.

The physicians also discuss whether or not these data, combined with those showing long-term safety and efficacy of the Admiral DCB, are enough for this treatment option to becoming standard of care in this challenging patient population.

This video is sponsored by Medtronic.


Please enter your comment!
Please enter your name here